From: DCIS and axillary nodal evaluation: compliance with national guidelines
Mastectomy Cohort (n = 31,912) | Breast Conservation Cohort (n = 55,349) | ||||||
---|---|---|---|---|---|---|---|
Variable | Yes | No | p-Value | Yes | No | p-Value | |
Year of Diagnosis | 1998 | 828(74.4%) | 285(25.6%) | <0.01 | 265(20.1%) | 1051(79.9%) | <0.01 |
1999 | 821(72.8%) | 306(27.2%) | 303(18.8%) | 1311(81.2%) | |||
2000 | 838(70.1%) | 358(29.9%) | 369(21.1%) | 1378(78.9%) | |||
2001 | 896(73.7%) | 319(26.3%) | 437(23.6%) | 1412(76.4%) | |||
2002 | 895(72.4%) | 342(27.6%) | 503(24.1%) | 1582(75.9%) | |||
2003 | 1146(74.9%) | 385(25.1%) | 819(26.5%) | 2272(73.5%) | |||
2004 | 1203(82.1%) | 262(17.9%) | 895(28.5%) | 2250(71.5%) | |||
2005 | 1345(82.5%) | 286(17.5%) | 1008(29.9%) | 2365(70.1%) | |||
2006 | 1544(85.1%) | 270(14.9%) | 1216(32.3%) | 2553(67.7%) | |||
2007 | 1939(87.5%) | 278(12.5%) | 1539(34.1%) | 2979(65.9%) | |||
2008 | 3471(91.3%) | 329(8.7%) | 2611(36.9%) | 4457(63.1%) | |||
2009 | 4142(91.3%) | 397(8.7%) | 3041(37.9%) | 4981(62.1%) | |||
2010 | 4151(93.5%) | 287(6.5%) | 2904(43%) | 3851(57%) | |||
2011 | 4286(93.4%) | 303(6.6%) | 3069(43.9%) | 3928(56.1%) | |||
Race | Black | 3144(86.5%) | 491(13.5%) | 0.52 | 2087(34.1%) | 4039(65.9%) | 0.02 |
White | 22682(86.2%) | 3638(13.8%) | 15954(34.5%) | 30246(65.5%) | |||
Other | 1335(85.3%) | 230(14.7%) | 761(31.9%) | 1628(68.1%) | |||
Age | 18–46 | 7089(88.5%) | 918(11.5%) | <0.01 | 5023(34.8%) | 9392(65.2%) | <0.01 |
47–55 | 7440(87.2%) | 1096(12.8%) | 5137(34.9%) | 9584(65.1%) | |||
56–65 | 6549(86.8%) | 992(13.2%) | 4743(35.6%) | 8594(64.4%) | |||
>65 | 6427(82.1%) | 1401(17.9%) | 4076(31.7%) | 8800(68.3%) | |||
Facility Type | Community Cancer Program | 2175(81%) | 511(19%) | <0.01 | 2133(36.4%) | 3731(63.6%) | <0.01 |
Comprehensive Community Cancer Program | 16873(86%) | 2757(14%) | 12474(36.6%) | 21632(63.4%) | |||
Academic/Research Program | 8457(88.1%) | 1139(11.9%) | 4372(28.4%) | 11007(71.6%) | |||
Facility Location | Midwest | 6742(86.2%) | 1079(13.8%) | <0.01 | 4169(31.4%) | 9128(68.6%) | <0.01 |
Northeast | 5267(86.7%) | 810(13.3%) | 3612(27.9%) | 9319(72.1%) | |||
South | 10642(86.8%) | 1623(13.2%) | 7738(41.2%) | 11023(58.8%) | |||
West | 4854(84.4%) | 895(15.6%) | 3460(33.4%) | 6900(66.6%) | |||
Primary Site | Nipple areolar | 223(79.1%) | 59(20.9%) | <0.01 | 94(26.7%) | 258(73.3%) | <0.01 |
Central | 1766(85.1%) | 310(14.9%) | 1047(30.7%) | 2368(69.3%) | |||
Upper inner | 1883(86.5%) | 294(13.5%) | 1629(34.1%) | 3153(65.9%) | |||
Lower inner | 1672(87.3%) | 244(12.7%) | 1123(32.9%) | 2288(67.1%) | |||
Upper outer | 7503(86.4%) | 1185(13.6%) | 7413(36.7%) | 12801(63.3%) | |||
Lower outer | 1861(86.8%) | 284(13.2%) | 1240(33.9%) | 2418(66.1%) | |||
Axillary tail | 31(86.1%) | 5(13.9%) | 51(48.1%) | 55(51.9%) | |||
Overlapping lesion | 6113(88%) | 835(12%) | 3723(34.2%) | 7175(65.8%) | |||
NOS | 6453(84.4%) | 1191(15.6%) | 2659(31.2%) | 5854(68.8%) | |||
Tumor Size | ≤1 cm | 4921(83.5%) | 970(16.5%) | <0.01 | 5605(30.3%) | 12878(69.7%) | <0.01 |
>1 cm, ≤2 cm | 5846(88.7%) | 745(11.3%) | 4903(40.7%) | 7139(59.3%) | |||
>2 cm, ≤3 cm | 1762(90%) | 195(10%) | 940(43.9%) | 1199(56.1%) | |||
>3 cm, ≤4 cm | 1376(89.6%) | 159(10.4%) | 647(45.3%) | 781(54.7%) | |||
>4 cm, ≤5 cm | 1178(91.7%) | 106(8.3%) | 363(45.1%) | 441(54.9%) | |||
>5 cm | 2526(92.8%) | 196(7.2%) | 535(45.2%) | 648(54.8%) |